ValGenesis | $16,000,000 | (Jul 23, 2025)
AbsoluteCare | $135,000,000 | (Jul 23, 2025)
Phlow | $37,000,000 | (Jul 23, 2025)
Syntis Bio
United States
- Boston, Massachusetts
- 02/07/2025
- Series A
- $38,000,000
Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine’s unique biology to provide accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for optimization in the small intestine, the body’s nexus for metabolic control, digestion and drug absorption. The company’s lead program, SYNT-101, is a once-daily oral pill for the treatment of obesity that mimics the effects of gastric bypass surgery. SYNT-101 leverages the power of SYNT™ (SYNthetic Tissue-lining), an oral technology developed by Syntis founders that delivers a safe, transient polymer coating to the duodenum that controls nutrient uptake, as well as enhances both gut-restricted enzyme efficacy and systemic drug absorption for up to 24 hours. Syntis is headquartered in Boston.
- Industry Biotechnology Research
- Website https://syntis.bio/
- LinkedIn https://www.linkedin.com/company/syntis-bio/
Related People
Rahul DhandaCo Founder
United States -
Boston, Massachusetts
I build industry-leading companies with great platform technologies for improving global health.
I have the honor of being the co-founder and CEO of Syntis Bio, which is exceptional for the technology, but mostly for the team. That team includes my co-founders Gio Traverso and Bob Langer, as well as all the amazing individuals working to make the company the best in the business. In 2018, I Co-founded Sherlock Biosciences, and I led the organization as its Founding CEO and President. I developed a first-rate team to create a path for CRISPR and Synthetic Biology to enter molecular diagnostics. Under my leadership, the company launched the first-ever CRISPR product, therapeutic or diagnostic, to be authorized by the FDA, paved the way for the next generation of molecular diagnostics, and has won numerous awards, including FastCompany Top 10 Most Innovative Biotech Companies, Red Herring Top 100, Fierce15 MedTech, and many more. I was personally recognized by the Boston Business Journal as one of its Power50 in 2020.
As an advocate for equity and representation, I have built Sherlock to maintain a diverse and inclusive culture that looks inward and outward to make a difference beyond technology. I am a Founding Board Member of The 221B Foundation, a non-profit that makes CRISPR IP available to any organization developing COVID diagnostics under the terms that our profit is invested in STEM education efforts to increase racial and gender diversity. My commitment to developing better healthcare tools while being a responsible corporate citizen is exemplified in my book, Guiding Icarus: Merging Bioethics with Corporate Interests, the first ethics and policy book written for the biotech industry.
I have developed my skills in public, Fortune 100 and early-stage, venture-backed companies, leading scientific, technology development, and commercial-scale activities. Whether at the bench or behind a desk, I have committed my whole career to creating financial and commercial success by bringing breakthrough healthcare platforms to the people who need them.
Composio | $25,000,000 | (Jul 23, 2025)
Nevoya | $9,300,000 | (Jul 23, 2025)
Delve | $32,000,000 | (Jul 23, 2025)
CandorIQ | $4,800,000 | (Jul 23, 2025)
BetterComp | $33,000,000 | (Jul 23, 2025)
Glīd | $3,100,000 | (Jul 22, 2025)
Cooler Heads Care | $11,000,000 | (Jul 22, 2025)
Alix | $20,000,000 | (Jul 22, 2025)
Nexxa.ai | $4,400,000 | (Jul 22, 2025)